Portal de recerca
- Inici
- Projectes i Estudis Clínics
- ESTUDIO ABIERTO, ALEATORIZADO, CONTROLADO, MULTICENTRICO DE FASE II PARA COMPARAR 5-FU/FA MAS OXALIPLATINO (FOSFOLX-4) MAS CETUXIMAB CON 5-FU/FA MAS OXALIPLATINO COMO TRATAMIENTO DE PRIMERA LINEA DEL CANCER COLORRECTAL METASTASICO QUE EXPRESA EL RECEPTORDEL FACTOR DE CRECIMIENTO EPIDERMICO.
ESTUDIO ABIERTO, ALEATORIZADO, CONTROLADO, MULTICENTRICO DE FASE II PARA COMPARAR 5-FU/FA MAS OXALIPLATINO (FOSFOLX-4) MAS CETUXIMAB CON 5-FU/FA MAS OXALIPLATINO COMO TRATAMIENTO DE PRIMERA LINEA DEL CANCER COLORRECTAL METASTASICO QUE EXPRESA EL RECEPTORDEL FACTOR DE CRECIMIENTO EPIDERMICO.
Dades bàsiques
- Protocol:
- EMR62202-047
- EURDRACT:
- 2005-000970-37
- NCT:
- Centre:
- Any inici:
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.
Okuno, Keisuke; (...); Goel, Ajay
Letter. 10.1186/s12943-022-01699-2. 2023
An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
Xu, Caiming; (...); Goel, Ajay
Article. 10.1158/1078-0432.CCR-24-1934. 2025
Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
Valladares-Ayerbes, M; (...); Vila, AL
Meeting Abstract. 10.1016/j.annonc.2021.08.976. 2021
Correction: Update on the management of elderly patients with colorectal cancer.
Soler-González G; (...); Gironés-Sarrió R
Correction. 10.1007/s12094-023-03351-x. 2024
Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study
Vera, R; (...); Viudez, A
Article. 10.3390/cancers12082259. 2020
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning.
Munoz, Andres J.; (...); Hernandez-Presa, Miguel Angel
Article. 10.1016/j.thromres.2023.06.015. 2023
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
Contreras-Toledo, Debora; (...); Carmona-Bayonas, Alberto
Article. 10.1038/s41416-023-02563-w. 2024
European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.
Boormans, Joost; (...); Laguna, Pilar
Meeting Abstract. 2023
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.
Valladares-Ayerbes M; (...); Lloansí Vila A
Article. 10.3390/cancers14246075. 2022
First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Oliveres, H.; (...); Maurel, J.
Meeting Abstract. 10.1016/j.annonc.2023.09.1796. 2023
Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)
Seidel, C; (...); Bokemeyer, C
Article. 10.1016/j.ejca.2020.03.022. 2020
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J
Article. 10.1007/s12094-024-03411-w. 2024
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Raga, Mireia Gil; (...); Hernandez, Isabel Busquier
Article. 10.1007/s12094-022-03047-8. 2023
Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease.
Aparicio J; (...); Fernandez-Montes A
Review. 10.3390/jcm9123889. 2020
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group.
Aparicio, J.; (...); Germa, J. R.
Article. 10.1007/s12094-020-02393-9. 2021
Precision medicine in metastatic colorectal cancer: targeting KRAS G12C mutation
Article. 10.21037/tgh-24-28. 2024
Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning.
Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel
Meeting Abstract. 2022
Predicting recurrence of venous thromboembolism in anticoagulated cancer patients using real-world data and machine learning.
Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel
Meeting Abstract. 2022
Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing.
Munoz Martin, Andres J; (...); Hernandez-Presa, Miguel Angel
Article. 10.1007/s12094-024-03586-2. 2024
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Boormans, Joost L; (...); Laguna, M Pilar
Article. 10.1016/j.euo.2023.10.014. 2023
Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study
Longo, F; (...); Sedano, MO
Meeting Abstract. 10.1016/j.annonc.2020.04.125. 2020
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
Aparicio, Jorge; (...); Maurel, Joan
Article. 10.1007/s12094-022-02868-x. 2022
Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)
Aparicio, J; (...); Maurel, J
Meeting Abstract. 10.1016/j.annonc.2021.08.937. 2021
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.
Longo F; (...); Díaz-Cerezo S
Article. 10.2217/fon-2020-1216. 2021
Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study.
López Muñoz AM; (...); Martín Gómez T
Article. 10.1007/s12094-024-03630-1. 2024
Recent treatment advances in clinical stage i nonseminomatous germ cell tumors.
Letter. 10.1016/j.acuro.2020.08.014. 2021
Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions
Vera Garcia, R.; (...); Mondejar Solis, R.
Meeting Abstract. 10.1016/j.annonc.2023.04.343. 2023
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022).
Fernandez Montes, Ana; (...); Aparicio, Jorge
Article. 10.1007/s12094-023-03199-1. 2023
SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).
Arranz Arija, Jose Angel; (...); Gonzalez-Billalabeitia, Enrique
Article. 10.1007/s12094-024-03532-2. 2024
Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study.
Valladares-Ayerbes M; (...); Lloansí Vila A
Article. 10.1007/s12094-024-03487-4. 2024
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; (...); Oing C
Article. 10.1007/s00345-021-03635-3. 2021
Update on the management of elderly patients with colorectal cancer.
Soler-Gonzalez, Gemma; (...); Girones-Sarrio, Regina
Article. 10.1007/s12094-023-03243-0. 2023
Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients
Munoz Martin, A.; (...); Angel Hernandez-Presa, M.
Meeting Abstract. 2022